Recently, the China Drug Administration approved the marketing of Opreton tablets, a Class 1 innovative drug declared by Takeda Pharmaceuticals U.S.A., Inc. for use in adolescents aged 16 and above and adults with type 1 narcolepsy. In addition, recently, the State Drug Administration approved the marketing of the Class 1 innovative drug siprocopan succinate tablets declared by Sichuan Hisco Pharmaceutical Co., Ltd. through a priority review and approval procedure. It is suitable for treating adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.